The present invention relates to a drug delivery system comprising a core and a shell in which the core comprises a hydrolytically degradable polymer X which polymer backbone comprises pendant ester and acid functionalities and in which the shell comprises a hydrolytic degradable polymer Y. The hydrolytic degradable polymers X and Y are different polymers. Polymer X further comprises amino-acids in the polymer backbone and degrades via zero order degradation kinetics for a period of at least 3 months. Polymer Y degrades via auto-acceleration degradation kinetics.

The present invention relates to the use of a liquid composition comprising one or more monomers for the production of a polyester, of a polyamide or of a polyesteramide, where at least one monomer is at least trifunctional, as binder in the binder-jetting process. The invention further relates to a process for the production of a shaped body by binder jetting.

The present invention relates to the use of a liquid composition comprising one or more monomers for the production of a polyester, of a polyamide or of a polyesteramide, where at least one monomer is at least trifunctional, as binder in the binder-jetting process. The invention further relates to a process for the production of a shaped body by binder jetting.

Synthesis of polyionenes with built-in degradable linkers through addition polymerization of a novel class of degradable A.sub.2-type monomers (d-A.sub.2), and their use as antimicrobial agents are disclosed. A library of biodegradable polyionenes and Gemini-surfactants made from d-A.sub.2 monomers are also disclosed. These materials have potent and broad spectrum of antimicrobial activity with high selectivity over mammalian cells.

Synthesis of polyionenes with built-in degradable linkers through addition polymerization of a novel class of degradable A.sub.2-type monomers (d-A.sub.2), and their use as antimicrobial agents are disclosed. A library of biodegradable polyionenes and Gemini-surfactants made from d-A.sub.2 monomers are also disclosed. These materials have potent and broad spectrum of antimicrobial activity with high selectivity over mammalian cells.

A method of preparing polyester elastomer meltblown nonwoven fabric membrane with porous and high bonding strength includes the following steps of: (a) Adding a reaction solvent to a reaction solvent to thermoplastic polyester elastomer (TPEE) powder or granules to prepare a solvent mixture. (b) Adding a modifier to the solvent mixture, and mixing uniformly to prepare a first mixture, the modifier includes at least one of o-xylylenediamine, m-xylylenediamine, alpha, alpha′-diamino-p-xylene, 2,3,5,6-Tetrachloro-p-xylene-alpha,alpha′-diamine, and 1,3,5,7-Tetraazatricyclodecane. (c) Adding an initiator to the first mixture, and mixing uniformly to prepare a second mixture. (d) Drying the second mixture to form a masterbatch, and (e) preparing the polyester elastomer meltblown nonwoven fabric membrane by passing the masterbatch through a meltblown process.

The present invention relates to a formulation sized for injection comprising a biodegradable polyesteramide co-polymer comprising at least a diol of bicyclic-1,4:3,6-dianhydrohexitol and analgesics for use in the treatment of arthritic disorders. More specific the invention relates to a formulation comprising injectable microparticle according to claim 1 wherein the polyesteramide co-polymer further comprises a diacid, a diol different from bicyclic-1,4:3,6-dianhydrohexitol and at least two different amino-acids. The formulation is used to treat pain or inflammation in a patient comprising administering to said patient a therapeutically effective amount of the formulation once or twice a year.

The present invention relates to a formulation sized for injection comprising a biodegradable polyesteramide co-polymer comprising at least a diol of bicyclic-1,4:3,6-dianhydrohexitol and analgesics for use in the treatment of arthritic disorders. More specific the invention relates to a formulation comprising injectable microparticle according to claim 1 wherein the polyesteramide co-polymer further comprises a diacid, a diol different from bicyclic-1,4:3,6-dianhydrohexitol and at least two different amino-acids. The formulation is used to treat pain or inflammation in a patient comprising administering to said patient a therapeutically effective amount of the formulation once or twice a year.

A polymer includes a repeating unit M and a repeating unit D, the repeating unit M is —COC.sub.6H.sub.6CONHCH.sub.2CH.sub.2O—, the repeating unit D is —COC.sub.6H.sub.6COOCH.sub.2CH.sub.2O—, and a molar ratio of the repeating unit M to the repeating unit D is 1:6 to 1:999.

A composite textile product includes a polyamide textile layer and a polyamide film. The polyamide film is bonded to the polyamide textile layer. A thickness of the polyamide textile layer is between 0.1 mm and 0.3 mm. The polyamide film has an average pore size ranging from 10 μm to 150 μm. A thickness of the polyamide film is between 0.01 mm and 0.1 mm. Wherein the polyamide film comprises a copolymer material, and the copolymer material includes a polyamide section and a polyether section.